Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series

Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series

Abstract Background Although relatively rare, rifampin mono-resistant tuberculosis (RMR TB) poses important challenges to effective TB treatment and control. Information on the burden of RMR TB and treatment outcomes is needed to inform diagnosis and management. Methods Standardized variables were c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2023-11, Vol.10 (11), p.ofad534-ofad534
Hauptverfasser: Lindsey, Joseph A, Easton, Alice V, Modestil, Herns, Dworkin, Felicia, Burzynski, Joseph, Nilsen, Diana
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page ofad534
container_issue 11
container_start_page ofad534
container_title Open forum infectious diseases
container_volume 10
creator Lindsey, Joseph A
Easton, Alice V
Modestil, Herns
Dworkin, Felicia
Burzynski, Joseph
Nilsen, Diana
description Abstract Background Although relatively rare, rifampin mono-resistant tuberculosis (RMR TB) poses important challenges to effective TB treatment and control. Information on the burden of RMR TB and treatment outcomes is needed to inform diagnosis and management. Methods Standardized variables were collected from the New York City (NYC) tuberculosis surveillance system for patients treated for RMR TB in NYC during 2010–2021. Results Of 7097 TB cases reported in 2010–2021, 31 (
doi_str_mv 10.1093/ofid/ofad534
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2895712476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofad534</oup_id><sourcerecordid>2895712476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c295t-cb9c4713f627f9eb4b2d0adbf62b24d6b5aee7d39efd5b6260b7fc7ec62b7fef3</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EEhV04wG8wdCA7VzcsFURN6mAVMrAZNnOsWRI42AnoG68A2_Ik-CqHZhYzu3_dHTOj9AJJeeUlOmFM7aOQdZ5mu2hEUvZNJmWOd__Ux-icQivhBBKSU54OUJiYY1cdbbF9651yQKCDb1se7wcFHg9NC4OcJQf4BO_OP-GK9uvJ5gRSn6-vhlh9BLP8AJ670IHurcfgCsZAD-BtxCO0YGRTYDxLh-h5-urZXWbzB9v7qrZPNGszPtEq1JnnKamYNyUoDLFaiJrFXvFsrpQuQTgdVqCqXNVsIIobjQHHXVuwKRH6Gy7t_PufYDQi5UNGppGtuCGINjmfcoyXkR0skV1PDl4MKLzdiX9WlAiNlaKjZViZ2XET7e4G7r_yV9k_Xa_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2895712476</pqid></control><display><type>article</type><title>Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lindsey, Joseph A ; Easton, Alice V ; Modestil, Herns ; Dworkin, Felicia ; Burzynski, Joseph ; Nilsen, Diana</creator><creatorcontrib>Lindsey, Joseph A ; Easton, Alice V ; Modestil, Herns ; Dworkin, Felicia ; Burzynski, Joseph ; Nilsen, Diana</creatorcontrib><description>Abstract Background Although relatively rare, rifampin mono-resistant tuberculosis (RMR TB) poses important challenges to effective TB treatment and control. Information on the burden of RMR TB and treatment outcomes is needed to inform diagnosis and management. Methods Standardized variables were collected from the New York City (NYC) tuberculosis surveillance system for patients treated for RMR TB in NYC during 2010–2021. Results Of 7097 TB cases reported in 2010–2021, 31 (&lt;1%) were treated clinically as RMR TB. Five (16%) of these patients had HIV. Seventeen patients (55%) had TB that was rifampin-resistant by both molecular and phenotypic drug susceptibility testing; 2 (6%) had rifampin resistance by phenotypic tests, and molecular tests were not done; and 12 (39%) were identified based only on molecular tests. Among these 12, 7 were rifampin-sensitive by phenotypic tests, and phenotypic testing could not be done for the other 5. Ten of the 31 (32%) were diagnosed in 2010–2015; the other 21 (including 10/12 diagnosed by molecular tests alone) were diagnosed in 2016–2021. Of the 31 patients, 21 (68%) completed treatment (median treatment duration of 18 months). Although the interval between tuberculosis treatment initiation and change to a non-rifamycin-containing regimen decreased significantly during the study period, the overall duration of treatment did not decrease significantly between 2010 and 2021. Conclusions Molecular drug susceptibility tests identified cases of RMR TB that were not detected by phenotypic testing and helped enable timely adjustment of tuberculosis treatment regimens. Short-course regimens are needed to reduce duration of treatment for RMR TB.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofad534</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Open forum infectious diseases, 2023-11, Vol.10 (11), p.ofad534-ofad534</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c295t-cb9c4713f627f9eb4b2d0adbf62b24d6b5aee7d39efd5b6260b7fc7ec62b7fef3</cites><orcidid>0000-0001-8846-7665 ; 0000-0002-7109-7669 ; 0000-0003-4344-8561 ; 0000-0002-4476-9415 ; 0000-0001-7031-6615</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,866,27933,27934</link.rule.ids></links><search><creatorcontrib>Lindsey, Joseph A</creatorcontrib><creatorcontrib>Easton, Alice V</creatorcontrib><creatorcontrib>Modestil, Herns</creatorcontrib><creatorcontrib>Dworkin, Felicia</creatorcontrib><creatorcontrib>Burzynski, Joseph</creatorcontrib><creatorcontrib>Nilsen, Diana</creatorcontrib><title>Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series</title><title>Open forum infectious diseases</title><description>Abstract Background Although relatively rare, rifampin mono-resistant tuberculosis (RMR TB) poses important challenges to effective TB treatment and control. Information on the burden of RMR TB and treatment outcomes is needed to inform diagnosis and management. Methods Standardized variables were collected from the New York City (NYC) tuberculosis surveillance system for patients treated for RMR TB in NYC during 2010–2021. Results Of 7097 TB cases reported in 2010–2021, 31 (&lt;1%) were treated clinically as RMR TB. Five (16%) of these patients had HIV. Seventeen patients (55%) had TB that was rifampin-resistant by both molecular and phenotypic drug susceptibility testing; 2 (6%) had rifampin resistance by phenotypic tests, and molecular tests were not done; and 12 (39%) were identified based only on molecular tests. Among these 12, 7 were rifampin-sensitive by phenotypic tests, and phenotypic testing could not be done for the other 5. Ten of the 31 (32%) were diagnosed in 2010–2015; the other 21 (including 10/12 diagnosed by molecular tests alone) were diagnosed in 2016–2021. Of the 31 patients, 21 (68%) completed treatment (median treatment duration of 18 months). Although the interval between tuberculosis treatment initiation and change to a non-rifamycin-containing regimen decreased significantly during the study period, the overall duration of treatment did not decrease significantly between 2010 and 2021. Conclusions Molecular drug susceptibility tests identified cases of RMR TB that were not detected by phenotypic testing and helped enable timely adjustment of tuberculosis treatment regimens. Short-course regimens are needed to reduce duration of treatment for RMR TB.</description><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kLtOwzAUhi0EEhV04wG8wdCA7VzcsFURN6mAVMrAZNnOsWRI42AnoG68A2_Ik-CqHZhYzu3_dHTOj9AJJeeUlOmFM7aOQdZ5mu2hEUvZNJmWOd__Ux-icQivhBBKSU54OUJiYY1cdbbF9651yQKCDb1se7wcFHg9NC4OcJQf4BO_OP-GK9uvJ5gRSn6-vhlh9BLP8AJ670IHurcfgCsZAD-BtxCO0YGRTYDxLh-h5-urZXWbzB9v7qrZPNGszPtEq1JnnKamYNyUoDLFaiJrFXvFsrpQuQTgdVqCqXNVsIIobjQHHXVuwKRH6Gy7t_PufYDQi5UNGppGtuCGINjmfcoyXkR0skV1PDl4MKLzdiX9WlAiNlaKjZViZ2XET7e4G7r_yV9k_Xa_</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Lindsey, Joseph A</creator><creator>Easton, Alice V</creator><creator>Modestil, Herns</creator><creator>Dworkin, Felicia</creator><creator>Burzynski, Joseph</creator><creator>Nilsen, Diana</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8846-7665</orcidid><orcidid>https://orcid.org/0000-0002-7109-7669</orcidid><orcidid>https://orcid.org/0000-0003-4344-8561</orcidid><orcidid>https://orcid.org/0000-0002-4476-9415</orcidid><orcidid>https://orcid.org/0000-0001-7031-6615</orcidid></search><sort><creationdate>20231101</creationdate><title>Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series</title><author>Lindsey, Joseph A ; Easton, Alice V ; Modestil, Herns ; Dworkin, Felicia ; Burzynski, Joseph ; Nilsen, Diana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c295t-cb9c4713f627f9eb4b2d0adbf62b24d6b5aee7d39efd5b6260b7fc7ec62b7fef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindsey, Joseph A</creatorcontrib><creatorcontrib>Easton, Alice V</creatorcontrib><creatorcontrib>Modestil, Herns</creatorcontrib><creatorcontrib>Dworkin, Felicia</creatorcontrib><creatorcontrib>Burzynski, Joseph</creatorcontrib><creatorcontrib>Nilsen, Diana</creatorcontrib><collection>Access via Oxford University Press (Open Access Collection)</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindsey, Joseph A</au><au>Easton, Alice V</au><au>Modestil, Herns</au><au>Dworkin, Felicia</au><au>Burzynski, Joseph</au><au>Nilsen, Diana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series</atitle><jtitle>Open forum infectious diseases</jtitle><date>2023-11-01</date><risdate>2023</risdate><volume>10</volume><issue>11</issue><spage>ofad534</spage><epage>ofad534</epage><pages>ofad534-ofad534</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract Background Although relatively rare, rifampin mono-resistant tuberculosis (RMR TB) poses important challenges to effective TB treatment and control. Information on the burden of RMR TB and treatment outcomes is needed to inform diagnosis and management. Methods Standardized variables were collected from the New York City (NYC) tuberculosis surveillance system for patients treated for RMR TB in NYC during 2010–2021. Results Of 7097 TB cases reported in 2010–2021, 31 (&lt;1%) were treated clinically as RMR TB. Five (16%) of these patients had HIV. Seventeen patients (55%) had TB that was rifampin-resistant by both molecular and phenotypic drug susceptibility testing; 2 (6%) had rifampin resistance by phenotypic tests, and molecular tests were not done; and 12 (39%) were identified based only on molecular tests. Among these 12, 7 were rifampin-sensitive by phenotypic tests, and phenotypic testing could not be done for the other 5. Ten of the 31 (32%) were diagnosed in 2010–2015; the other 21 (including 10/12 diagnosed by molecular tests alone) were diagnosed in 2016–2021. Of the 31 patients, 21 (68%) completed treatment (median treatment duration of 18 months). Although the interval between tuberculosis treatment initiation and change to a non-rifamycin-containing regimen decreased significantly during the study period, the overall duration of treatment did not decrease significantly between 2010 and 2021. Conclusions Molecular drug susceptibility tests identified cases of RMR TB that were not detected by phenotypic testing and helped enable timely adjustment of tuberculosis treatment regimens. Short-course regimens are needed to reduce duration of treatment for RMR TB.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofad534</doi><orcidid>https://orcid.org/0000-0001-8846-7665</orcidid><orcidid>https://orcid.org/0000-0002-7109-7669</orcidid><orcidid>https://orcid.org/0000-0003-4344-8561</orcidid><orcidid>https://orcid.org/0000-0002-4476-9415</orcidid><orcidid>https://orcid.org/0000-0001-7031-6615</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2328-8957
ispartof Open forum infectious diseases, 2023-11, Vol.10 (11), p.ofad534-ofad534
issn 2328-8957
2328-8957
language eng
recordid cdi_proquest_miscellaneous_2895712476
source DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central
title Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T08%3A03%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rifampin%20Mono-Resistant%20Tuberculosis%20in%20New%20York%20City,%202010%E2%80%932021:%20A%20Retrospective%20Case%20Series&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Lindsey,%20Joseph%20A&rft.date=2023-11-01&rft.volume=10&rft.issue=11&rft.spage=ofad534&rft.epage=ofad534&rft.pages=ofad534-ofad534&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofad534&rft_dat=%3Cproquest_cross%3E2895712476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2895712476&rft_id=info:pmid/&rft_oup_id=10.1093/ofid/ofad534&rfr_iscdi=true